Hexarelin was demonstrated to have greater potency than ghrelin treatment in improving LV function after myocardial infarction in ghrelin deficient mice, which was suggested to be due to the possible binding of hexarelin to cardiac GHS-R1a and CD36 (class B scavenger receptor involved in fatty acid uptake) receptors (Mao et al., 2013a). The gene discussed is GHRL; the disease is myocardial infarction.